• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Savara closes $130M offering

March 15, 2021 By Sean Whooley

SavaraSavara (NSDQ:SVRA) announced today that it closed its previously announced public offering with proceeds reaching approximately $130 million.

Austin, Texas-based Savara last week announced the offering of 45.8 million shares of its common stock to the public for $1.45 per share, expecting proceeds of $113 million.

However, the company today said in a news release that it sold about 57.5 million shares of common stock, including nearly 11.7 million shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares.

Additionally, the company sold pre-funded warrants to purchase an aggregate of 32.2 million shares of common stock at a purchase price of $1.449 per warrant. Jefferies and Piper Sandler acted as joint book-running managers and representatives of the underwriters for the offering. Oppenheimer & Co. acted as the lead manager and H.C. Wainwright & Co., acted as co-manager for the offering.

Savara said the net proceeds from the offering will be used to support its operations, including development, manufacturing, regulatory and commercial activities related to its molgramostim nebulizer solution (molgramostim, formerly referred to as Molgradex) for treating autoimmune pulmonary alveolar proteinosis (aPAP) — and the IMPALA 2 trial.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup Tagged With: Savara Inc.

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS